Patents by Inventor Antoine Molaro

Antoine Molaro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11744843
    Abstract: The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: September 5, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Jay Francis Sarthy, Antoine Molaro, Marie Bleakley, Guo-Liang Chew
  • Publication number: 20220133760
    Abstract: The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 5, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jay Francis Sarthy, Antoine Molaro, Marie Bleakley, Guo-Liang Chew